cyrilzakka/clinical-trials huggingface dataset:
Supper Heroes: Examining the Impact of an Online Eating Intervention for Families

This study will examine the effectiveness of the online family-based program focused on sustainable eating compared to weekly emails about environmentally friendly behaviours.

The investigators will conduct a family-level RCT following CONSORT guidelines: families will be randomly allocated into control and intervention groups. The control group will receive an email once a week for 7 weeks with information about environmentally friendly habits.

The intervention group will participate in the 7-week online Supper Heroes program consisting of 7 online "missions" completed over 7 weeks. Each mission includes tasks for families to complete, including reading infographics, watching short videos, participating in family-based activities, and sharing their progress. Parents will receive 2 text messages each week with information about the program. Families will also receive a toolkit to support their participation which will contain cookbooks, a potato brush, grocery planning tools, and a note that orients them to what is included. It will take approximately 1-2 hours per mission to complete all activities.

* Infographics: Each mission will contain brief, 1-2-page infographics for families to read. Topics are related to the mission theme for that week. For example, families may learn about tips for grocery shopping and meal planning as well as information about plant-based proteins.
* Videos: Similar to the infographics, short, 1-5-minute online videos will be related to the theme of the mission participants are completing. For example, families will watch a short, animated video about grocery shopping.
* Family-based activities: During each mission, participants will be invited to participate in a family-based activity such as follow-along cooking videos, doing an audit of their fridge, and creating a grocery shopping list.
* Sharing: Families will be asked to share their experiences for each mission on an online community share board by providing a photo and/or text.

Eligibility Criteria:
Inclusion Criteria:

* have at least one child 9-12 years old
* live in Ontario, Canada
* have access to the internet
* can respond to English surveys

Exclusion Criteria:

* parent(s) with prior nutrition and food education (e.g., degree in nutrition, culinary arts training)
* families with food allergies that would prevent them from participating in the intervention (e.g., soy products, beans or lentils)
* families who are vegetarian or vegan
Can Synbiotic Use Effect Gut Bacteria and the Immune Response in Older People

The objectives of this study are to use a nutritional change in the diet to improve gut health in older people. Ageing can result in major changes in the composition and activities of the bacteria in your gut, leading to a higher incidence of gastrointestinal infections, decreased intestinal motility and impaired bowel function as people get older. This can result in constipation or diarrhoea, increased levels of inflammation and reduced immune response to infection. Therefore, individuals aged 65 or over could benefit from safe and effective interventions that maintain a healthy balance of gut bacteria as well as restoring the immune response. Bacteria in the gut are known to promote health. Eating foods containing beneficial bacteria for example (probiotics) or food which contain substrates for the bacteria to grow on (prebiotics) can improve the balance of gut bacteria. The investigators will use a synbiotic with known anti-inflammatory properties, comprising a probiotic Bifidobacterium longum strain and inulin (Synergy 1), The synbiotic has been previously shown to be beneficial in reducing inflammation and to increase levels of beneficial bacteria in the gut in two studies in patients with inflammatory bowel disease. The investigators would now for these reasons, like to determine the effects of our Synbiotic on the gut bacteria and immune function of older individuals in a double-blinded, crossover, placebo controlled, randomised investigation involving 40 volunteers for three months. The trial is designed so that participants will be assigned to receive the Synbiotic preparation or the placebo for the first four weeks, this will be followed by four weeks without treatment, and then they will switch to the opposite preparation for another four weeks.


Eligibility Criteria:
Inclusion Criteria:

* 65-90 years
* BMI 18.5-30.0 kg m2.

Exclusion Criteria:

* asplenia and other acquired or congenital immunodeficiencies
* any autoimmune disease
* connective tissue diseases
* self-reported symptoms of acute or recent infection (including use of antibiotics within the previous 3 months)
* taking probiotics or prebiotics, including lactulose for constipation
* chronic gastrointestinal problems (e.g. Inflammatory bowel disease, irritable bowel syndrome, cancer)
* use of immunosuppressive or anti-inflammatory drugs.
STELLA 2 Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer

The purpose of this study is to determine whether or not there are more complications in the extraperitoneal compared with the transperitoneal approach for laparoscopic aortic lymphadenectomy for the surgical staging of endometrial or ovarian cancer


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of endometrial cancer confirmed by histopathological analysis (endometrial biopsy) requiring surgical staging according to FIGO (the International Federation of Gynecology and Obstetrics) recommendations
* Diagnosis of ovarian cancer confirmed by histopathological analysis after an initial cystectomy or oophorectomy without suspicion of neoplasia thus requiring additional surgical staging according to FIGO recommendations

Exclusion Criteria:

* Diagnosis of advanced endometrial cancer based on findings on imaging techniques (CT, MRI and/or PET)
* Diagnosis of advanced endometrial or ovarian cancer based on intraoperative findings (e.g. peritoneal carcinomatosis at initial laparoscopy)
* Patients who underwent previous aortic lymphadenectomy
* Patients who received previous pelvic and/or aortic radiotherapy
Experimental Design of Couple Counseling and Testing in Antenatal Clinics in Dar es Salaam, Tanzania

The objective of this research is to evaluate the effectiveness of couples Voluntary Counseling and Testing for HIV (CVCT) compared to individual VCT (IVCT) in preventing MTCT, and in increasing preventive behaviors and minimizing spousal abuse among HIV positive women. We hypothesize that offering CVCT will not decrease uptake of VCT among women. This research will be carried out in 3 antenatal clinics in Dar es Salaam, Tanzania.


Eligibility Criteria:
Inclusion Criteria:

* Up to 6 months of pregnancy
* Currently married or in cohabiting union for 2+ years and co-resident with husband

Exclusion Criteria:

* In polygamous marriage
* 7 or more months pregnant
Impact of Disney Movies During Chemotherapy on QOL of Gynecologic Oncology Patients

To evaluate the impact of Disney movies on quality of life (QOL) of gynecologic oncology patients.

25 Patients are watching Disney movies on portable DVD players during chemotherapy, 25 patients are not allowed to watch TV.

EORTC QLQ-C30 and EORTC QLQ-FA12 surveys are given to the patients before and after the six chemotherapies.

Hypothesis: Disney movies can elevate patients QOL.


Eligibility Criteria:
Inclusion Criteria:

* planned 6 cycles of chemotherapy with carboplatin/paclitaxel or carboplatin/pegylated liposomal doxorubicin
* Age \>18 years

Exclusion Criteria:

* inadequate knowledge of the German language
Folic Acid Salt Study (FISFA Zambia)

Question: How effective is fortified iodized salt with folic acid (FISFA) in increasing serum and red blood cell folate in non-lactating, non-pregnant women of reproductive age in the country of Zambia who do not have active food fortification with a folic acid program?

Participants will:

* Consume salt with folic acid instead of their regular salt for 6 months
* Have a blood draw 4 times
* Fill out surveys

The objective of this nonrandomized controlled intervention trial is to measure the effectiveness of fortified iodized salt with folic acid (FISFA) on increasing blood folate concentrations as a preventive measure against folate-sensitive neural tube defects (NTDs) in a non-fortifying country of Zambia.

The main questions it aims to answer are:

Aim 1: Measure the effectiveness of FISFA on increasing serum and red blood cell folate concentrations in women of reproductive age in a non-fortifying country.

Aim 2: Assess the risk of neural tube defects by measuring folate insufficiency levels via serum and red blood cell concentrations in women of reproductive age in a non-fortifying country.

Aim 3: Assess taste and color acceptability of FISFA by study population.

Eligibility Criteria:
Inclusion Criteria:

* Voluntary participation in the study
* Do not intend to get pregnant
* Not lactating or pregnant
* Live alone or with a partner if they can be compliant and not share the study salt.
* Aged between 18 and 45 years

Exclusion Criteria:

* Pregnant or lactating
Comparison Between Remifentanil Target-controlled Infusion and Dexmedetomidine Bolus Administration for Smooth Emergence From General Sevoflurane Anesthesia

Remifentanil target-controlled infusion and dexmedetomidine single-dose administration are known to reduce airway response and haemodynamic stimulation during anaesthetic recovery. The investigators will compare the effects of two drugs on prevention of cough during emergence from general sevoflurane anaesthesia.


Eligibility Criteria:
Inclusion Criteria:

* female patient,
* aged 20-60 yr,
* ASA physical status 1-2,
* patients undergoing elective thyroidectomy under general anesthesia

Exclusion Criteria:

* sighs of difficult airway,
* history of respiratory disease or chronic cough,
* cardiovascular disease,
* pregnant or breast-feeding woman.
Serological Profile of Children and Young Adolescents With at Least One COVID-19 Diagnosed Family Member

Use of rapid serological tests to assess the vulnerability to SARS-CoV-2 infection of subjects aged 4-16 years old and cohabiting with at least one family member who tested positive to SARS-CoV-2

Families with at least one child or young adult aged between 4 and 16 years old and with at least one cohabitant who tested positive to nasopharyngeal swab are contacted by phone. Those who decide to sign an informed consent after reading the study information will be included in the study. It consists of a preliminary telephone interview and a following rapid serological test for all children and young adults with the age included in the range of interest and the cohabitant who tested positive to nasopharingeal swab.

The obtained results will be collected and analysed, and the outcomes of the study will be measured.

Eligibility Criteria:
Inclusion Criteria:

1. Children and young adults aged between 4 and 16 years old with at least a Sars-Cov-2 positive cohabitant
2. Adults who previously tested positive to SARS-CoV-2 with at least a cohabitant aged between 4 and 16 y.o.
3. Subjects from the district of Sesto San Giovanni, Lombardy, Italy

Exclusion Criteria:

1. Children and young adults aged between 4 and 16 years old without at least a cohabitant who previously tested positive to SARS-CoV-2
2. Adults who previously tested positive to SARS-CoV-2 without at least a cohabitant aged between 4 and 16 y.o.
3. Absence of a signed informed consent
4. Subject with symptoms suggestive of COVID-19 in the last 14 days or disease in progress
Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease

The objective of this study is to evaluate the pharmacokinetics of deferiprone and its 3-O-glucuronide metabolite following administration of a single 1500 mg dose of Ferriprox in patients with sickle cell disease.

This is a single-arm, single-dose study of Ferriprox in patients with sickle cell disease. Patients found to be eligible will visit the clinic the day before receiving the drug, in order to reconfirm eligibility and to undergo baseline assessments, and will receive a single dose of 1500 mg Ferriprox under fasting conditions. Blood and urine samples for pharmacokinetic assessment will be collected over a 10-hour period. Standard safety assessments will be performed throughout the study, and patients will return for a safety follow-up.

Eligibility Criteria:
Inclusion Criteria:

1. Male or female, 18-45 years of age (inclusive)
2. Diagnosis of sickle cell disease, confirmed by Hb electrophoresis
3. Body weight ≥ 50 kg
4. Body mass index (BMI) ≥ 18 and ≤ 32 kg/m\^2
5. Absolute neutrophil count (ANC) of \>1.5 x 10\^9/L
6. Women of childbearing potential must agree to either be sexually inactive or use an acceptable method of birth control for 14 days prior to dosing and for 30 days afterwards
7. A fertile heterosexual male must agree that he or his partner will use an effective method of contraception for 14 days prior to dosing and for 30 days afterwards

Exclusion Criteria:

1. History or presence of hypersensitivity or idiosyncratic reaction to Ferriprox
2. Use of Ferriprox within the past 3 months
3. History of malignancy
4. Evidence of abnormal liver function (serum Alanine Transaminase (ALT)level \> 5 times upper limit of normal or creatinine levels \>2 times upper limit of normal)
5. A serious, unstable illness, as judged by the Investigator, within the past 3 months before screening visit including but not limited to hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or immunologic disease
6. Hemodialysis during the week prior to dosing or planned for the day of dosing
7. Known difficulty in providing blood samples
8. Disorders or surgery of the gastrointestinal tract that may interfere with drug absorption or may otherwise influence the Pharmacokinetic (PK) results (e.g., resection of the small or large intestine, febrile conditions, chronic diarrhea, chronic vomiting, endocrine disease, severe infections, acute inflammations, etc.)
9. Clinically significant abnormalities on 12-lead ECG (e.g., QT interval corrected using Fridericia's formula (QTcF) ≥ 430 ms in males or ≥ 450 ms in females)
10. Use of tobacco/nicotine-containing products for at least 3 months prior to study drug administration
11. Use of any drugs within the past 14 days that are metabolized by the Uridine diphosphate glucosyltransferase enzyme (UGT1A6) and hence could affect the PK of Ferriprox
12. Treatment with an investigational drug within the past 30 days or 5 half-lives of that drug (whichever is longer) prior to study drug administration
13. Pregnant or nursing female
Faculty and Students' Attitude Toward E-learning

E-learning in medical education is a relatively new idea that is rapidly growing. This study aimed to assess the students and faculty staff attitude for e-learning at the emergence of COVID-19.

A prospective cross-sectional online survey based on Google form was conducted at a medical university in Iraq between March and April 2020

E learning provides education at a generally lower cost and engages learners at a time and location that is most appropriate for them. Recent calls for reform in medical education and training have emphasized the use of information technology-empowered learning. This was enhanced more in the COVID-19 era . Some international organizations, such as the World Health Organization (WHO), have acknowledged e-learning as a helpful tool for healthcare education, particularly in developing countries. Nevertheless, the use of e-learning by the faculty members and students stayed minimum for uploading lecture notes, course books, feedbacks, and providing marks until the COVID-19 pandemic raised that need. This study aimed to evaluate faculty and students' knowledge and attitudes toward e-learning at the emergence of COVID-19 and identify the potential requirements for implementing e-learning.

An online survey was distributed to a sample of 190 faculty and 1706 students of a medical university in Iraq. Knowledge and attitudes towards e-learning were studied

Eligibility Criteria:
Inclusion Criteria:

* undergraduate students faculty staff working in Hawler Medical University

Exclusion Criteria:

* Faculty staff who are on leave for study or health purpose
Effects of 24-week Computerized Cognitive Training in Patients With MCI and AD

This study aims to testify multi-domain effects of computerized cognitive training in patients with mild cognitive impairment and mild Alzheimer's disease through multi-dimensional evaluation.

This study aimed to elucidate the neural process enhancement and remodulation in gut microbes resulting from older adults with MCI and mild AD in a randomized controlled trial of a 24-week computerized cognitive training (CCT) program.

After recruitment and baseline assessments, pairs of participants with MCI and mild AD would be randomly allocated into the corresponding subgroup. Participants in CCT group will receive a computerized multidomain cognitive training program (www.66nao.com) and will be required to complete at least 30 minutes of training per day (3 cycle of 5 2-min tasks), 5 days a week for 24 weeks. Adherence to the intervention will be supervised by an independent researcher. The number of training days and training hours per day will be recorded. Patients in control group received treatment as usual (TAU) for 24 weeks. The neuropsychological measures will be performed at baseline, follow-up at 4 weeks, 12 weeks, and 24 weeks; functional Near-Infrared Spectroscopy (fNIRS) data and fecal samples will collected at baseline and 24 weeks.

Eligibility Criteria:
Inclusion Criteria:

* between 55 and 90 years of age;
* a Clinical Dementia Rating (CDR) score of 0.5 or 1;
* at least three months of stable doses if receiving antidementia medication or mood-stabilizing medication for mild AD participants;
* primary school education and above;
* accompanied by a consistent caregiver (at least 5 days/week);
* informed consent.

Exclusion Criteria:

* factors that might preclude completion of assessments;
* severe psychiatric illness and the use of antidepressants;
* any condition that would preclude completion of training and follow-up tests;
* other disorders that would affect cognition.
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE

Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE

The investigators conduct this clinical trial to evaluate the treatment outcome of RFA in HCC patients with tumor smaller than 7cm and tumor number less than five ,in comparison with TACE treatment.The primary outcome is overall survival.The secondary outcome is objective response rate.

Eligibility Criteria:
Inclusion criteria:

* age 18 to 75 years ;
* HCC confirmed by pathological or clinical diagnosis according to the American Association for the Study of Liver Diseases criteria ;
* solitary HCC less than 7cm in diameter or multiple HCC lesions less 5
* the absence of portal/hepatic vein invasion, lymph node involvement and extrahepatic metastases;
* lesions visible on ultrasound with a safe path between the lesion and skin;
* an Eastern Cooperative Oncology Group performance status of 0-1;
* Child-Pugh class A or B cirrhosis.

The exclusion criteria :

* received any other previous treatment for HCC;
* severe coagulation disorders;
* evidence of hepatic decompensation including hepatic encephalopathy, ascites as well as esophageal or gastric variceal bleeding;
* presence of serious medical comorbidities, including serious dysfunction of the heart or kidney ;
* currently had other malignancies in addition to HCC.
Promoting Resilience to Food Commercials Decreases Susceptibility to Unhealthy Food Decision-Making

The purpose of this study is to evaluate how food commercials influence food choices in children and their parents.

The proposed research will investigate food decision-making in youth. Childhood obesity is a risk factor for health issues, thus preventing adverse effects of childhood obesity by promoting healthy eating habits and providing effective interventions are important. Television food commercials advertising calorie-dense and high in salt and sugar foods are known to contribute unhealthy food choices and obesity. Thus the proposed study will examine how the advertising intervention focusing on increasing advertising knowledge and changing affective attitudes toward commercials impacts susceptability to commercials and food decisions in youth.

Eligibility Criteria:
Inclusion Criteria:

* Children had to be between 8-12.9 years old (including 8 year olds, NOT including 13 year olds.
* Had to be able to speak English as their primary language.
* Self-reported normal hearing and vision.

Exclusion Criteria:

* Did not speak English
* Data from children with history of neurological conditions, clinically significant psychopathology, or learning disabilities reported by parents (e.g., Attention Deficit Hyperactivity Disorder, depression) will be excluded.
The Role of Vitamin D, A, and Beta Carotene in Tuberculosis Patients With Vitamin D Receptor Gene Polymorphism

Recent studies showed that vitamin D and A has an effect in improving sputum conversion in tuberculosis. This study aims to find out the effect of vitamin D 1000 IU and A 6000 IU supplementation on Tuberculosis patients with vitamin D receptor gene polymorphism, who live in North Sumatera, Indonesia. This study is a randomized control clinical trial, with 48 tuberculosis patients with vitamin D receptor gene polymorphism which are TaqI and FokI participating, divided into two groups, each with 24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU, and control group (C) which only receives nutritional counseling for 28 days. Patients who participated was found to be heterozygous with TaqI (T\>C) or FokI (C\>T) genotype variants.

Recent studies showed that vitamin D and A has an effect in improving sputum conversion in tuberculosis. This study aims to find out the effect of vitamin D 1000 IU and A 6000 IU supplementation on Tuberculosis patients with vitamin D receptor gene polymorphism, who live in North Sumatera, Indonesia. This study is a randomized control clinical trial, with 48 tuberculosis patients with vitamin D receptor gene polymorphism which are TaqI and FokI participating, divided into two groups, each with 24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU, and control group (C) which only receives nutritional counseling for 28 days. Patients who participated was found to be heterozygous with TaqI (T\>C) or FokI (C\>T) genotype variants. The result of this study showed that at the start, serum 25(OH)D levels in group I were lower compared to group C (19.746.59 ng/mL vs 25.21±7.57 ng/mL). Group I showed significant correlation between vitamin D level categories with sputum conversion (mean: standard deviation= 2.25±0.68 weeks). Supplementation of vitamin D 1000 IU provides an accelerated sputum conversion in tuberculosis patients with vitamin D receptor gene polymorphism.

Eligibility Criteria:
Inclusion Criteria:

* The inclusion criteria are males or females, which have new case lung tuberculosis infection with acid fast bacilli (AFB) result (+), aged 18-60 years, heterozygote genotype test on one of the genes TaqI and FokI, willing to participate in the study and complete the informed consent.

Exclusion Criteria:

* The exclusion criteria are pregnant, found to have comorbidities such as diabetes mellitus or Human Immunodeficiency Virus (+), and Tuberculosis on category II.